Fig. 5

Interactions of Oligo-tau and pS396-tau-laden RGCs with brain pathology and cognitive status. (a-d) Spearman’s rank correlation coefficient (r_S) analyses of pS396-tau⁺ RGCs (count) or T22⁺ Oligo-tau⁺ RGCs (count) with (a, b) brain Aβ plaque severity scores or (c, d) brain neurofibrillary tangles (NFTs) severity scores. (e, f) Quantitative pS396-tau⁺ RGC and Oligo-tau⁺ RGC cell counts per Braak stage stratification (n = 22–23). (g, h) Spearman’s r_S correlations of (g) pS396-tau⁺ RGCs (count) or (h) Oligo-tau⁺ RGCs (count) with the Braak stage. (i-m) Spearman’s r_S correlations of pS396-tau⁺ RGCs (count) or Oligo-tau⁺ RGCs (count) with (i-k) average brain ABC scores (k for MCI due-to-AD and AD dementia patients only), and with (l-m) clinical dementia rating (CDR) scores. (n, o) Quantitative pS396-tau⁺ RGC and Oligo-tau⁺ RGC cell counts when patients are stratified according to 26-score cutoff on the mini-mental state examination (MMSE; n = 16–17). (p-r) Spearman’s r_S correlations between pS396-tau⁺ RGCs or Oligo-tau⁺ RGCs cell counts and MMSE scores (r for MCI due-to-AD and AD dementia patients only). Bar graphs display individual data points and mean ± SEM. *P < 0.05, **P < 0.01, by one-way ANOVA followed by Tukey’s post-hoc multiple comparison test. Two group comparison is determined by unpaired Student t-test. ABC scores comprise of mean grades for: (A) Aβ plaque score modified from Thal, (B) NFT stage modified from Braak, and (C) neuritic plaque score modified from CERAD